IL184051A - Acetylated GLP-1 compounds, containing and using pharmaceutical preparations - Google Patents

Acetylated GLP-1 compounds, containing and using pharmaceutical preparations

Info

Publication number
IL184051A
IL184051A IL184051A IL18405107A IL184051A IL 184051 A IL184051 A IL 184051A IL 184051 A IL184051 A IL 184051A IL 18405107 A IL18405107 A IL 18405107A IL 184051 A IL184051 A IL 184051A
Authority
IL
Israel
Prior art keywords
compounds
medicaments
manufacture
pharmaceutical compositions
acylated glp
Prior art date
Application number
IL184051A
Other languages
English (en)
Hebrew (he)
Other versions
IL184051A0 (en
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36821525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL184051(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL184051A0 publication Critical patent/IL184051A0/en
Publication of IL184051A publication Critical patent/IL184051A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
IL184051A 2005-03-18 2007-06-19 Acetylated GLP-1 compounds, containing and using pharmaceutical preparations IL184051A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05102171 2005-03-18
PCT/EP2006/060855 WO2006097537A2 (en) 2005-03-18 2006-03-20 Acylated glp-1 compounds

Publications (2)

Publication Number Publication Date
IL184051A0 IL184051A0 (en) 2007-10-31
IL184051A true IL184051A (en) 2015-08-31

Family

ID=36821525

Family Applications (1)

Application Number Title Priority Date Filing Date
IL184051A IL184051A (en) 2005-03-18 2007-06-19 Acetylated GLP-1 compounds, containing and using pharmaceutical preparations

Country Status (24)

Country Link
US (2) US8129343B2 (cg-RX-API-DMAC10.html)
EP (2) EP1863839B1 (cg-RX-API-DMAC10.html)
JP (3) JP5209463B2 (cg-RX-API-DMAC10.html)
KR (1) KR101205272B1 (cg-RX-API-DMAC10.html)
CN (3) CN101133082B (cg-RX-API-DMAC10.html)
AT (1) ATE476446T1 (cg-RX-API-DMAC10.html)
AU (1) AU2006224536B9 (cg-RX-API-DMAC10.html)
BE (1) BE2018C016I2 (cg-RX-API-DMAC10.html)
BR (2) BRPI0607762B8 (cg-RX-API-DMAC10.html)
CA (1) CA2601784C (cg-RX-API-DMAC10.html)
DE (1) DE602006015928D1 (cg-RX-API-DMAC10.html)
DK (2) DK1863839T3 (cg-RX-API-DMAC10.html)
ES (2) ES2350051T3 (cg-RX-API-DMAC10.html)
HU (2) HUE028194T2 (cg-RX-API-DMAC10.html)
IL (1) IL184051A (cg-RX-API-DMAC10.html)
MX (1) MX2007011220A (cg-RX-API-DMAC10.html)
NL (1) NL300936I2 (cg-RX-API-DMAC10.html)
NO (2) NO337946B1 (cg-RX-API-DMAC10.html)
PL (2) PL1863839T3 (cg-RX-API-DMAC10.html)
PT (2) PT2322546E (cg-RX-API-DMAC10.html)
RU (1) RU2434019C3 (cg-RX-API-DMAC10.html)
TW (2) TWI362392B (cg-RX-API-DMAC10.html)
WO (1) WO2006097537A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200707261B (cg-RX-API-DMAC10.html)

Families Citing this family (245)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
EP2932981B1 (en) * 2003-09-19 2021-06-16 Novo Nordisk A/S Albumin-binding derivatives of GLP-1
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
KR20070120112A (ko) * 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 연장형 ｇｌｐ-1 화합물
CN100374462C (zh) * 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 截短胰高血糖素样肽1(sGLP-1)、制法及其应用
MX2008012678A (es) 2006-04-07 2008-12-17 Merrion Res Iii Ltd Forma de dosis oral solida que contiene un mejorador.
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) * 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8226949B2 (en) * 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US20090326193A1 (en) * 2006-06-23 2009-12-31 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
CN101842386A (zh) * 2007-09-05 2010-09-22 诺沃-诺迪斯克有限公司 截短的glp-1衍生物和它们的治疗用途
WO2009030771A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
JP5476304B2 (ja) 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
PT2597103T (pt) 2007-11-16 2017-02-08 Novo Nordisk As Composições farmacêuticas contendo insulina e um péptido insulinotrófico
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
KR101755434B1 (ko) 2008-03-18 2017-07-10 노보 노르디스크 에이/에스 프로테아제 안정화되고, 아실화된 인슐린 유사체
EP2271347B1 (en) 2008-03-28 2016-05-11 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
CA2723541A1 (en) 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
RU2526804C2 (ru) * 2008-08-06 2014-08-27 Ново Нордиск Хелс Кеа Аг Конъюгированные белки с пролонгированным действием in vivo
JP5591243B2 (ja) 2008-09-12 2014-09-17 ノボ・ノルデイスク・エー／エス ペプチド又はタンパク質のアシル化の方法
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
KR20110122100A (ko) 2009-01-22 2011-11-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 안정한 성장 호르몬 화합물
CN102361647B (zh) 2009-01-23 2018-02-16 诺沃-诺迪斯克有限公司 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用
JP2012529463A (ja) * 2009-06-11 2012-11-22 ノヴォ ノルディスク アー／エス ２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ
CN104961822A (zh) 2009-07-13 2015-10-07 西兰制药公司 酰化胰高血糖素类似物
CN102612376A (zh) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
US8648041B2 (en) 2009-12-16 2014-02-11 Novo Nordisk A/S Double-acylated GLP-1 derivatives
AU2011208620B2 (en) 2010-01-22 2015-04-16 Novo Nordisk Health Care Ag Stable growth hormone compounds
TWI508737B (zh) 2010-01-22 2015-11-21 諾佛 儂迪克股份有限公司 具有延長的活體內功效的生長激素
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
US20130035285A1 (en) 2010-03-26 2013-02-07 Novo Nordisk A/S Novel glucagon analogues
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
CN102186881B (zh) * 2010-04-27 2015-04-08 贝达药业股份有限公司 胰高血糖素样肽-1衍生物及其应用
EP2565205B1 (en) * 2010-04-27 2015-07-01 Betta Pharmaceuticals Co., Ltd. Glucagon-like peptide-1 analogue and use thereof
CN103124739B (zh) * 2010-05-17 2015-11-25 贝达药业股份有限公司 一种新胰高血糖素样肽类似物、组合物及其用途
WO2012016419A1 (zh) * 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
CN103209711B (zh) 2010-11-09 2016-04-13 诺沃—诺迪斯克有限公司 双-酰化的glp-1衍生物
RS56998B1 (sr) * 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
CA2819234A1 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
JP2014502984A (ja) 2011-01-19 2014-02-06 ノヴォ ノルディスク アー／エス Ｇｌｐ−１組成物
EP2665470A1 (en) 2011-01-19 2013-11-27 Novo Nordisk A/S Glp-1 particles and compositions
CA2830974A1 (en) * 2011-03-28 2012-10-04 Jesper F. Lau Novel glucagon analogues
JP5871905B2 (ja) * 2011-03-30 2016-03-01 ベータ ファーマシューティカルズ カンパニー リミテッド グルカゴン様ペプチド−１類似体およびその使用
MY161450A (en) * 2011-04-12 2017-04-14 Novo Nordisk As Double-acylated glp-1 derivatives
KR102093463B1 (ko) * 2011-04-12 2020-03-26 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
PT3415139T (pt) 2011-06-14 2022-06-20 Neurelis Inc Administração de benzodiazepina
BR112014001274A2 (pt) 2011-07-18 2017-04-18 Arts Biologics As composto de hormônio luteinizante, e, composição farmacêutica
US9758560B2 (en) 2011-09-06 2017-09-12 Novo Nordisk A/S GLP-1 derivatives
EP2758426B1 (en) 2011-09-23 2019-08-07 Novo Nordisk A/S Novel glucagon analogues
KR101922164B1 (ko) 2011-12-29 2019-02-13 노보 노르디스크 에이/에스 비-단백질원 아미노산을 포함하는 디펩티드
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
HRP20181817T1 (hr) 2012-02-15 2018-12-28 Novo Nordisk A/S Anitijela koja vezuju protein 1 prepoznavanja peptidoglikana
SI2814844T1 (sl) 2012-02-15 2017-10-30 Novo Nordisk A/S Protitelesa, ki vežejo in blokirajo sprožilni receptor, izražen na mieloidnih celicah-1 (trem-1)
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
LT2827885T (lt) 2012-03-22 2018-10-10 Novo Nordisk A/S Glp-1 peptidų kompozicijos ir jų gavimas
PT2827885T (pt) * 2012-03-22 2018-11-05 Novo Nordisk As Composições de péptidos glp-1 e sua preparação
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
EA028665B1 (ru) 2012-05-03 2017-12-29 Зилэнд Фарма А/С Соединения - двойные агонисты gip-glp-1 и способы
WO2013167454A1 (en) 2012-05-08 2013-11-14 Novo Nordisk A/S Double-acylated glp-1 derivatives
CN104411322B (zh) * 2012-05-08 2017-05-24 诺和诺德股份有限公司 双酰化glp‑1衍生物
US9745359B2 (en) 2012-05-18 2017-08-29 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
JP6517690B2 (ja) * 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
HUE049152T2 (hu) 2012-07-01 2020-09-28 Novo Nordisk As Hosszantartó hatású GLP-1 peptidek alkalmazása
JP6534927B2 (ja) 2012-07-23 2019-06-26 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014060472A1 (en) 2012-10-17 2014-04-24 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
JP6672140B2 (ja) 2013-05-02 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１化合物の経口投薬
KR20160021183A (ko) * 2013-06-20 2016-02-24 노보 노르디스크 에이/에스 Glp-1 유도체 및 그것의 용도
US9498534B2 (en) 2013-07-04 2016-11-22 Novo Nordisk A/S Derivatives of GLP-1 like peptides, and uses thereof
EP3033112B1 (en) 2013-08-15 2020-10-07 Novo Nordisk A/S Glp-1 derivatives, and uses thereof
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
US10286078B2 (en) 2013-09-13 2019-05-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CN119119233A (zh) 2013-10-17 2024-12-13 西兰制药公司 酰化胰高血糖素类似物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
US10626156B2 (en) 2013-12-06 2020-04-21 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
CN106456589B (zh) 2013-12-18 2020-07-07 斯克利普斯研究所 修饰的治疗剂、订合的肽脂质缀合物及其组合物
AR100306A1 (es) 2014-02-18 2016-09-28 Novo Nordisk As Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia
CN106132985B (zh) 2014-04-07 2020-10-13 诺和诺德股份有限公司 双酰化glp-1化合物
TWI668010B (zh) 2014-05-07 2019-08-11 丹麥商諾佛 儂迪克股份有限公司 使用ｇｌｐ－１及抗ｉｌ－２１治療糖尿病
WO2015185640A1 (en) 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
KR102641268B1 (ko) 2014-07-17 2024-02-27 노보 노르디스크 에이/에스 점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발
US10968266B2 (en) 2014-09-05 2021-04-06 University Of Copenhagen GIP peptide analogues
GR20140100479A (el) * 2014-09-23 2016-05-05 Novetide, Ltd., Συνθεση λιραγλουτιδης
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
KR102620911B1 (ko) 2014-10-29 2024-01-05 질랜드 파마 에이/에스 Gip 효능제 화합물 및 방법
JP6730278B2 (ja) * 2014-11-27 2020-07-29 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
CN107108714B (zh) 2014-12-17 2022-02-08 诺和诺德股份有限公司 Glp-1衍生物及其用途
TWI681966B (zh) 2014-12-23 2020-01-11 丹麥商諾佛 儂迪克股份有限公司 Ｆｇｆ２１衍生物及其用途
US20180263915A1 (en) * 2015-01-29 2018-09-20 Novo Nordisk A/S Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
AU2016247499B2 (en) 2015-04-16 2020-09-03 Zealand Pharma A/S Acylated glucagon analogue
WO2016203495A1 (en) * 2015-06-16 2016-12-22 Sun Pharma Advanced Research Company Limited Long acting liraglutide compositions
EP3310376A4 (en) 2015-06-17 2019-01-23 The California Institute for Biomedical Research MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
CN106554403B (zh) * 2015-09-25 2021-08-31 博瑞生物医药（苏州）股份有限公司 艾塞那肽修饰物及其用途
CN106554409B (zh) * 2015-09-30 2020-04-07 天津药物研究院有限公司 一种长效胰高血糖素样肽-1类似物及其应用
CN106554408A (zh) * 2015-09-30 2017-04-05 天津药物研究院有限公司 长效胰高血糖素样肽-1类似物二聚体及其应用
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
CN106928343A (zh) * 2015-12-30 2017-07-07 深圳翰宇药业股份有限公司 索玛鲁肽的制备方法
ES2835033T3 (es) 2016-03-03 2021-06-21 Novo Nordisk As Derivados de GLP-1 y sus usos
CN107266557B (zh) * 2016-04-06 2020-04-07 天津药物研究院有限公司 一种聚乙二醇修饰的胰高血糖素样肽-1类似物
ES2928007T3 (es) 2016-04-28 2022-11-14 Novo Nordisk As Semaglutida en afecciones cardiovasculares
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
WO2018078112A1 (en) 2016-10-27 2018-05-03 Aarhus Universitet Glp-1 agonist (eg liraglutide) for use in the treatment of multiple sclerosis
JP7076442B2 (ja) 2016-11-07 2022-05-27 ノヴォ ノルディスク アー／エス Ｐｅｇ化合物のｄｃｈｂｓ活性エステル及びその使用
DK3554534T3 (da) 2016-12-16 2021-08-23 Novo Nordisk As Farmaceutisk sammensætning omfattende insulin
CN107033234B (zh) * 2017-01-03 2018-06-26 北京凯因科技股份有限公司 酰化的glp-1衍生物
JP2020510028A (ja) * 2017-03-08 2020-04-02 インターシア セラピューティクス，インコーポレイティド 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法
BR112019025195A8 (pt) 2017-05-31 2020-07-07 Univ Copenhagen análogos do peptídeo gip de ação prolongada
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CA3068956A1 (en) * 2017-07-19 2019-01-24 Novo Nordisk A/S Bifunctional compounds
MA46990B1 (fr) 2017-08-24 2024-03-29 Novo Nordisk As Compositions glp-1 et ses utilisations
MA50233A (fr) 2017-09-10 2020-07-22 Novo Nordisk As Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité
EP3689942B1 (en) 2017-09-29 2024-06-19 Hanmi Pharm. Co., Ltd. Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method therefor
IL322969A (en) * 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical therapy
CN107881187A (zh) * 2017-11-20 2018-04-06 珠海联邦制药股份有限公司 将大肠杆菌表达的融合蛋白转化为利拉鲁肽的制备方法及应用
US11186608B2 (en) 2017-12-21 2021-11-30 Bachem Holding Ag Solid phase synthesis of acylated peptides
MX2020007598A (es) 2018-02-02 2020-09-03 Novo Nordisk As Composiciones solidas que comprenden un agonista del peptido similar al glucagon tipo 1 (glp-1), una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante.
CN110294800B (zh) * 2018-03-22 2022-03-04 齐鲁制药有限公司 一种索玛鲁肽的制备方法
MA52190A (fr) 2018-04-02 2021-02-17 Bristol Myers Squibb Co Anticorps anti-trem-1 et utilisations associées
PL4122954T3 (pl) 2018-04-05 2024-08-12 Sun Pharmaceutical Industries Limited Nowe analogi GLP-1
JP7442823B2 (ja) 2018-04-06 2024-03-05 シプルメット・ゲーエムベーハー 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
WO2019200594A1 (zh) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
CN110386974B (zh) * 2018-04-19 2022-12-09 杭州先为达生物科技有限公司 Glp-1衍生物及其治疗用途
TWI707865B (zh) 2018-05-04 2020-10-21 丹麥商諾佛 儂迪克股份有限公司 Gip衍生物及其用途
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
PE20211492A1 (es) * 2018-10-26 2021-08-11 Novo Nordisk As Composiciones estables de semaglutida y usos de las mismas
CN109180801B (zh) * 2018-11-01 2021-08-13 汉肽生物医药集团有限公司 一种合成索玛鲁肽的方法
BR112021010447A2 (pt) 2018-12-03 2021-08-24 Antag Therapeutics Aps Análogos de peptídeos gip modificados
EP3897570A1 (en) 2018-12-19 2021-10-27 KRKA, d.d., Novo mesto Pharmaceutical composition comprising glp-1 analogue
CN113194929B (zh) 2018-12-21 2022-12-09 诺和诺德股份有限公司 Glp-1肽的喷雾干燥工艺
EA202091615A1 (ru) 2018-12-21 2021-03-05 Аегис Терапьютикс, Ллс Интраназальные составы на основе эпинефрина и способы лечения заболевания
US20220072493A1 (en) 2019-01-24 2022-03-10 Novo Nordisk A/S Roller compactor and method of dry granulation using a roller compactor
SG11202108254YA (en) 2019-02-12 2021-08-30 Ambrx Inc Compositions containing, methods and uses of antibody-tlr agonist conjugates
MA55008A (fr) 2019-02-20 2021-12-29 Novo Nordisk As Aminoacyl-arnt synthétases et leurs utilisations
WO2020187712A1 (en) 2019-03-15 2020-09-24 Novo Nordisk A/S Process for spray drying a glp-1 peptide
WO2020190757A1 (en) 2019-03-15 2020-09-24 Novetide Ltd. Improved processes for the preparation of semaglutide
CN111748019A (zh) * 2019-03-29 2020-10-09 深圳翰宇药业股份有限公司 一种多肽衍生化合物的合成方法
JP7712210B2 (ja) 2019-04-01 2025-07-23 ノヴォ ノルディスク アー／エス リラグルチドに対する抗体およびその使用
MX2021012277A (es) * 2019-04-11 2021-11-12 Jiangsu Hansoh Pharmaceutical Group Co Ltd Agonista multireceptor y uso medico del mismo.
CN111909256A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 多肽衍生物及其制备方法
CN113840619A (zh) * 2019-05-21 2021-12-24 免疫医疗有限公司 Sglt2抑制剂和肠促胰岛素肽的基于环糊精的可注射共配制品
BR112022002189A2 (pt) 2019-09-02 2022-04-26 Novo Nordisk As Processo de produção de um comprimido, e, comprimido
AU2020349493A1 (en) * 2019-09-16 2022-04-07 Biomarin Pharmaceutical Inc. CNP variants and conjugates thereof
CN110590934B (zh) * 2019-09-25 2020-12-08 北京乐普医药科技有限公司 一种glp-1化合物
CA3154744A1 (en) 2019-11-06 2021-05-14 Sarah FRIEDRICH Glp-1 receptor agonists in dementia
CN114641276A (zh) 2019-11-07 2022-06-17 诺和诺德股份有限公司 包含glp-1激动剂、sglt2抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
EP3819308A1 (en) 2019-11-07 2021-05-12 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of derivatized amino acids
WO2021105393A1 (en) 2019-11-29 2021-06-03 Novo Nordisk A/S Processes for obtaining stable glp-1 compositions
WO2021123228A1 (en) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
CN119529057A (zh) 2019-12-30 2025-02-28 甘李药业股份有限公司 长效glp-1化合物
CN113597434B (zh) 2019-12-31 2022-07-01 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
MA58498B1 (fr) 2020-02-07 2024-08-30 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
JP7548600B2 (ja) 2020-02-14 2024-09-10 ジー２ジーバイオ インコーポレイテッド Ｇｌｐ－１アナログ、またはその薬学的に許容可能な塩を含む徐方型微粒球を含む薬学的組成物
TW202535454A (zh) 2020-02-18 2025-09-16 丹麥商諾佛 儂迪克股份有限公司 醫藥配方
CN111253475B (zh) * 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 Glp-1激动多肽化合物及其盐与合成方法及用途
US20230295077A1 (en) 2020-04-10 2023-09-21 Fresenius Kabi Oncology Limited An improved process for the preparation of semaglutide side chain
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
WO2021219710A1 (en) 2020-04-29 2021-11-04 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
AR122579A1 (es) * 2020-06-12 2022-09-21 Lilly Co Eli Proceso para preparar un agonista dual glp-1 / glucagón
CA3184723A1 (en) 2020-07-22 2022-01-27 Patrick J. KNERR Glp-1 and gip receptor co-agonists
IL300155A (en) 2020-08-06 2023-03-01 Gasherbrum Bio Inc Heterocyclic glp-1 agonists
US20230302150A1 (en) 2020-08-20 2023-09-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
CN116419750A (zh) 2020-09-07 2023-07-11 西普鲁梅有限公司 改进的glp-1受体激动剂的药物制剂
WO2022068920A1 (en) 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
JP7484018B2 (ja) 2020-11-06 2024-05-15 ノヴォ ノルディスク アー／エス Ｇｌｐ－１プロドラッグおよびその使用
TW202440619A (zh) 2020-12-18 2024-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
BR112023019389A2 (pt) 2021-03-25 2023-11-28 Brightgene Bio Medical Tech Co Ltd Compostos, agonista de receptor duplo de gip e glp-1, composição farmacêutica compreendendo os mesmos, uso dos mesmos e método para prevenir e/ou tratar doenças associadas a distúrbios metabólicos
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
TW202304500A (zh) 2021-04-21 2023-02-01 瑞士商諾華公司 升糖素樣肽化合物
MX2023014771A (es) 2021-06-09 2024-03-19 Scripps Research Inst Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.
EP4351630A1 (en) 2021-06-10 2024-04-17 Antag Therapeutics ApS Treatment of obesity and obesity-related disorders
EP4360623A4 (en) 2021-06-23 2025-06-04 Peptron, Inc. DELAYED-RELEASE FORMULATION CONTAINING SEMAGLUTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
WO2022268214A1 (zh) 2021-06-25 2022-12-29 甘李药业股份有限公司 Pcsk9抑制剂和glp-1受体激动剂的药物组合
EP4360645A4 (en) * 2021-06-25 2025-09-10 Gan & Lee Pharmaceuticals Co Ltd PHARMACEUTICAL COMPOSITION CONTAINING A GLP-1 COMPOUND
WO2023285347A1 (en) 2021-07-12 2023-01-19 Novo Nordisk A/S Novel fatty acid modified urocortin 2 derivatives and the uses thereof
EP4288461A4 (en) 2021-07-14 2025-07-02 Beijing Ql Biopharmaceutical Co Ltd FUSION POLYPEPTIDES FOR METABOLIC DISORDERS
US20240335388A1 (en) 2021-07-15 2024-10-10 Novo Nordisk A/S Tablet comprising a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN116410297A (zh) * 2021-07-19 2023-07-11 内蒙古博睿精创科技有限公司 长效glp-1多肽类似物及其制备方法和应用
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
WO2023038039A1 (ja) 2021-09-08 2023-03-16 塩野義製薬株式会社 抗肥満作用の関与する疾患の予防及び治療用医薬
KR20240126450A (ko) 2021-11-10 2024-08-20 아이투오 테라퓨틱스, 인코포레이티드 이온성 액체 조성물
WO2023110833A1 (en) 2021-12-13 2023-06-22 Novo Nordisk A/S Pharmaceutical formulations comprising a cyclodextrin
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
US20250206757A1 (en) 2022-03-21 2025-06-26 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
CA3252113A1 (en) 2022-03-30 2023-10-05 Beijing Ql Biopharmaceutical Co., Ltd. Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use
EP4499127A1 (en) 2022-03-30 2025-02-05 Novo Nordisk A/S Formulation method
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20250304645A1 (en) 2022-05-10 2025-10-02 Novo Nordisk A/S Prodrugs of GLP-1 Polypeptide and Uses Thereof
US20250195617A1 (en) 2022-05-23 2025-06-19 Ascendis Pharma Growth Disorders A/S Liquid Pharmaceutical Formulations of CNP Compounds
IL318154A (en) 2022-07-05 2025-03-01 G2Gbio Inc A composition containing a microsphere for sustained release of semaglutide pharmaceutical salt and methods for making the same
WO2024068848A1 (en) 2022-09-28 2024-04-04 Zealand Pharma A/S Methods for treating obesity
WO2024079043A1 (en) 2022-10-10 2024-04-18 Bachem Holding Ag Method of manufacturing a peptide with a lysine derivative
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
TW202421645A (zh) 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如ｇｌｐ—１之肽治療劑的口服投與
JP2025539630A (ja) 2022-12-16 2025-12-05 ペプトロン インコーポレイテッド Ｇｌｐ－１受容体アゴニストまたはその薬学的に許容可能な塩を含む徐放性微粒球およびその用途
CN116159027A (zh) * 2022-12-29 2023-05-26 江苏诺泰澳赛诺生物制药股份有限公司 一种司美格鲁肽冻干药物组合物及其制备方法
KR20250141711A (ko) 2022-12-30 2025-09-29 알지파마 에이에스 경구 투여되는 폴리펩타이드 치료제의 전신 생체이용률을 증가시키는 조성물 및 방법
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2024179606A1 (zh) * 2023-03-02 2024-09-06 甘李药业股份有限公司 一种glp-1化合物的医药用途
KR20250169638A (ko) 2023-03-06 2025-12-03 아센디스 파마 에이에스 알부민 결합 모이어티를 갖는 약물의 화합물
EP4676535A1 (en) 2023-03-06 2026-01-14 Ascendis Pharma A/S Multi-albumin binding compounds
WO2024184352A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Drug compounds comprising albumin-binding moieties
KR20250162619A (ko) 2023-03-20 2025-11-18 아센디스 파마 그로우쓰 디스오더스 에이/에스 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법
WO2024199734A2 (en) 2023-03-30 2024-10-03 Novo Nordisk A/S Fusion compounds and uses thereof
WO2024234320A1 (zh) * 2023-05-17 2024-11-21 南京知和医药科技有限公司 一种长效胰高血糖素样肽-1衍生物及其制备方法和用途
AU2024284396A1 (en) 2023-06-09 2026-01-08 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
KR20240176455A (ko) 2023-06-15 2024-12-24 노보 노르디스크 에이/에스 시클로덱스트린을 포함하는 약학적 제형
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity
WO2025077751A1 (zh) * 2023-10-09 2025-04-17 甘李药业股份有限公司 Glp-1肽组合物及其用途
WO2025078040A1 (en) 2023-10-09 2025-04-17 Bachem Holding Ag Lysine salt and method of manufacturing a lysine derivative
WO2025106773A1 (en) 2023-11-17 2025-05-22 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent
WO2025114501A1 (en) 2023-11-30 2025-06-05 Novo Nordisk A/S Tri-agonists of the glp-1, gip, and amylin receptors
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
US20250326814A1 (en) 2024-02-06 2025-10-23 Opko Biologics Ltd. Modified oxyntomodulin and methods of use thereof
WO2025172606A1 (en) 2024-02-16 2025-08-21 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603080A1 (en) 2024-02-16 2025-08-20 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4684801A1 (en) 2024-07-23 2026-01-28 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025172605A1 (en) 2024-02-16 2025-08-21 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4684802A1 (en) 2024-07-23 2026-01-28 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603079A1 (en) 2024-02-16 2025-08-20 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
GB202403746D0 (en) 2024-03-15 2024-05-01 New Roger Randal Charles Formulations demonstrating an oral depot effect
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity
WO2025248124A1 (en) 2024-05-31 2025-12-04 Zealand Pharma A/S Dapiglutide for use in treating a sub-group of subjects
WO2026008836A1 (en) 2024-07-05 2026-01-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
WO2026013136A1 (en) 2024-07-10 2026-01-15 Ascendis Pharma A/S Albumin-binding compounds
WO2026013138A1 (en) 2024-07-10 2026-01-15 Ascendis Pharma A/S Compounds with improved albumin-binding
WO2026013135A1 (en) 2024-07-10 2026-01-15 Ascendis Pharma A/S Albumin-binding reagents

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04504246A (ja) 1989-03-20 1992-07-30 ザ・ジェネラル・ホスピタル・コーポレーション インシュリン刺激ホルモン
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ES2113879T3 (es) 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1998008872A1 (en) 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-2 derivatives
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP1826216A1 (en) * 1996-08-30 2007-08-29 Novo Nordisk A/S Glp-1 derivatives
ATE466028T1 (de) * 1998-02-27 2010-05-15 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
AU2610599A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
ATE265224T1 (de) 1998-02-27 2004-05-15 Novo Nordisk As Glp-1 derivate mit einem helix-gehalt über 25 , die partiell strukturierte mizellenartige aggregate bilden
WO1999043361A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
CZ295889B6 (cs) 1998-12-07 2005-11-16 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající arginin na pozicích 26 a 34, jejich použití a farmaceutické prostředky je obsahující
DK1180121T3 (da) 1999-05-17 2004-03-01 Conjuchem Inc Langtidsvirkende insulinotrope peptider
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
EP1250126A2 (en) 2000-01-11 2002-10-23 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
JP2004528014A (ja) 2000-12-07 2004-09-16 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１融合タンパク質
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
US7186797B2 (en) 2001-08-10 2007-03-06 Epix Pharmaceuticals, Inc. Polypeptide conjugates with extended circulating half-lives
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
BR0306706A (pt) 2002-01-08 2007-03-27 Lilly Co Eli peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica
CA2513044A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
MXPA04009929A (es) 2002-04-10 2006-03-10 Lilly Co Eli Tratamiento de la gastroparesis.
EP2067483A1 (en) 2003-02-19 2009-06-10 Ipsen Pharma Analogues of GLP-1
ES2390270T3 (es) 2003-03-19 2012-11-08 Eli Lilly And Company Compuestos de GLP-1 unidos a polietilenglicol
JP2007524584A (ja) * 2003-05-09 2007-08-30 ノボ　ノルディスク　アクティーゼルスカブ 肥満の治療に使用するペプチド
JP2007501811A (ja) * 2003-08-08 2007-02-01 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 治療的な関心対象のタンパク質に対する遅延分子の選択的な化学物質接合のためのガラクトースオキシダーゼの使用。
RU2401276C2 (ru) 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
EP2932981B1 (en) * 2003-09-19 2021-06-16 Novo Nordisk A/S Albumin-binding derivatives of GLP-1
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
KR20060135661A (ko) 2003-12-18 2006-12-29 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 화합물
CN101665538A (zh) 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
EP2292272A3 (en) 2004-07-08 2011-10-26 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
JP5175103B2 (ja) 2004-11-12 2013-04-03 ノヴォ ノルディスク アー／エス 安定なペプチド製剤
EP1863537A2 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
KR20070120112A (ko) 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 연장형 ｇｌｐ-1 화합물
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds

Also Published As

Publication number Publication date
RU2434019C2 (ru) 2011-11-20
EP2322546B1 (en) 2015-09-30
JP4585037B2 (ja) 2010-11-24
RU2434019C3 (ru) 2020-07-20
DE602006015928D1 (de) 2010-09-16
BR122019002626A2 (cg-RX-API-DMAC10.html) 2019-04-02
BRPI0607762B8 (pt) 2021-05-25
JP2013063984A (ja) 2013-04-11
WO2006097537A3 (en) 2007-01-25
US8536122B2 (en) 2013-09-17
RU2007134156A (ru) 2009-04-27
CN101133082A (zh) 2008-02-27
BRPI0607762A2 (pt) 2010-03-23
ZA200707261B (en) 2008-05-28
DK1863839T3 (da) 2010-11-22
NL300936I2 (nl) 2018-08-07
NO2018023I1 (cg-RX-API-DMAC10.html) 2018-07-05
ES2350051T3 (es) 2011-01-17
KR101205272B1 (ko) 2013-01-11
CN104402989A (zh) 2015-03-11
AU2006224536B2 (en) 2012-04-05
EP1863839B1 (en) 2010-08-04
BRPI0607762B1 (pt) 2019-05-07
JP2008533105A (ja) 2008-08-21
TWI372629B (en) 2012-09-21
ATE476446T1 (de) 2010-08-15
CA2601784C (en) 2013-12-24
MX2007011220A (es) 2007-10-17
PL2322546T3 (pl) 2016-03-31
HUE028194T2 (en) 2016-12-28
US20120295847A1 (en) 2012-11-22
HUS1800019I1 (hu) 2018-06-28
JP5209463B2 (ja) 2013-06-12
BE2018C016I2 (cg-RX-API-DMAC10.html) 2025-09-05
JP2010116407A (ja) 2010-05-27
NO337946B1 (no) 2016-07-18
NO20075342L (no) 2007-12-18
PT1863839E (pt) 2010-11-10
PL1863839T3 (pl) 2011-01-31
DK2322546T3 (en) 2015-12-14
IL184051A0 (en) 2007-10-31
KR20070120089A (ko) 2007-12-21
CN101133082B (zh) 2016-01-13
US8129343B2 (en) 2012-03-06
EP1863839A2 (en) 2007-12-12
ES2557313T3 (es) 2016-01-25
TW200942255A (en) 2009-10-16
WO2006097537A2 (en) 2006-09-21
TW200700433A (en) 2007-01-01
EP2322546A1 (en) 2011-05-18
AU2006224536B9 (en) 2012-05-10
TWI362392B (en) 2012-04-21
PT2322546E (pt) 2016-01-22
US20090156478A1 (en) 2009-06-18
CA2601784A1 (en) 2006-09-21
CN104017062A (zh) 2014-09-03
AU2006224536A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
IL184051A (en) Acetylated GLP-1 compounds, containing and using pharmaceutical preparations
IL213597A0 (en) Compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
IL231576A (en) Derivatives of adamantyl-acetamide, the pharmaceutical compositions containing them and their use in the preparation of medicines
IL181524A (en) Heterocyclic compounds, pharmaceuticals containing them and their use in the preparation of drugs
IL183101A (en) Use of tetrahydrocannabivarin in drug production
IL174647A (en) Pyrazolopyridines and analogs thereof, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
IL182427A (en) Sulphonil-preserved bicyclic compounds, including pharmaceutical preparations and their use in the manufacture of pharmaceuticals
ZA200707653B (en) Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments
IL191984A0 (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
IL193678A (en) Derivatives of pyrazolyl-theophane, pharmaceuticals containing them and their use in the preparation of drugs to improve cognitive activity
IL185484A0 (en) Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
IL177283A (en) Pyrazolopyrimidine compounds, their use in the preparation of medicines and pharmaceuticals containing them
TW200612910A (en) Medicaments comprising carbonyl compounds, and the use thereof
IL201176A (en) 4-amino-1-h-pyrazolo [3,4- d] pyrimidine-3-ram-phenyl, a pharmaceutical containing them and their use in the preparation of a drug
IL179714A (en) Pharmaceutical preparation containing a history of 2-biphenyl-4-ram-3,2-dehydro-1h-quinazoline-4-on and its use in the preparation of cancer drugs and blood vessel formation
IL183108A (en) Triazole Compounds, Containing and Using Pharmaceutical Preparations for the Treatment of Prosperity Irregularities
IL184712A (en) History of pyrzulo-pyrimidine, process of preparation, medicinal preparations containing them and use of pharmaceutical preparations
IL191310A (en) A variant of the factor xa enhancer hemostasis, a pharmaceutical product containing it, and its use in the preparation of drugs for the treatment of hemostasis-related diseases
IL209879A0 (en) Substituted pteridines ,pharmaceutical compositions containing them and their use in the manufacture of medicaments for treating inflammatory diseases
IL201730A (en) History 1h - Benzaimidazole – 2 – Il – Profile – Methyl – Amino – Ethyl – 5 – Aryl – Bicyclo [2.2.2] Oct – 5 – Ann – 2 – All, Pharmaceutical preparations containing them and their use in the preparation of drugs
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders
IL190636A0 (en) Quinazoline derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments useful for treating or preventing flaviviridae infection
IL178939A (en) Double and triple combinations suitable for synergistic treatment of breast cancer, including pharmaceuticals and their use in the manufacture of drugs and drugs for the treatment of breast cancer
SI1803456T1 (sl) Farmacevtski sestavki, ki obsegajo L-733060, za uporabo pri zdravljenju rakavih tumorjev

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
EXTF Application for patent extension filed

Filing date: 20190507

PEL Intention of commissioner to extend period of protection

Free format text: PRODUCT NAME: SEMAGLUTIDE

Extension date: 20310319

KB Patent renewed